Clinical Trial Update: Study to Investigate the Efficacy and Safety of Mexiletine in Patients With Myotonic Dystrophy Type 1 and Type 2 [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating mexiletine for myotonic dystrophy type 1 and type 2 has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myotonic Dystrophy Type

Drugs mentioned

• Mexiletine (Mexiletine)

Snippet

Sponsor: Lupin Ltd. | Conditions: Myotonic Dystrophy Type 1 and Type 2 | Phase 3 | Status: WITHDRAWN